26 Article(s)Download |
||||||
PMID | Title | Pub. Year | #Total Relationships |
|||
1 | 33994798 | Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report. | 2021 | 1 | ||
2 | 34026823 | Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. | 2021 | 2 | ||
3 | 34033974 | Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706). | 2021 Sep | 2 | ||
4 | 34761117 | Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report. | 2021 | 1 | ||
5 | 31231786 | A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. | 2020 Apr | 3 | ||
6 | 31918452 | Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185). | 2020 Mar | 1 | ||
7 | 32351894 | Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. | 2020 | 2 | ||
8 | 32508029 | Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. | 2020 Jun | 4 | ||
9 | 32642151 | Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. | 2020 May | 3 | ||
10 | 30608421 | Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. | 2019 Jan | 1 | ||
11 | 30702616 | Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report. | 2019 Feb | 1 | ||
12 | 30706337 | Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. | 2019 Aug | 2 | ||
13 | 31073278 | Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. | 2019 | 1 | ||
14 | 31570733 | Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. | 2019 Sep 30 | 2 | ||
15 | 31699150 | The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). | 2019 Nov 7 | 3 | ||
16 | 29467959 | Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. | 2018 Jan 23 | 4 | ||
17 | 29575765 | Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. | 2018 May | 3 | ||
18 | 29740957 | EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. | 2018 Jul | 2 | ||
19 | 30003733 | An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving gene(s). | 2018 May-Jun | 1 | ||
20 | 30038504 | Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. | 2018 | 1 | ||
21 | 30170427 | Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis. | 2018 Aug | 2 | ||
22 | 30344715 | Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. | 2018 Nov | 1 | ||
23 | 28176910 | Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. | 2017 | 2 | ||
24 | 28490886 | Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. | 2017 | 3 | ||
25 | 28822888 | Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. | 2017 Oct | 6 | ||
26 | 29029508 | Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. | 2017 Sep 12 | 3 |